DrugPatentWatch Database Preview
Pfizer Company Profile
» See Plans and Pricing
What is the competitive landscape for PFIZER, and when can generic versions of PFIZER drugs launch?
PFIZER has one hundred and thirty-five approved drugs.
There are thirty-eight US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.
There are seven hundred and fifty-two patent family members on PFIZER drugs in sixty-seven countries and one hundred and forty-four supplementary protection certificates in eighteen countries.
Summary for Pfizer
| International Patents: | 752 |
| US Patents: | 38 |
| Tradenames: | 106 |
| Ingredients: | 95 |
| NDAs: | 135 |
| Drug Master File Entries: | 3 |
| Patent Litigation for Pfizer: | See patent lawsuits for Pfizer |
| PTAB Cases with Pfizer as petitioner: | See PTAB cases with Pfizer as petitioner |
Drugs and US Patents for Pfizer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | UNASYN | ampicillin sodium; sulbactam sodium | INJECTABLE;INJECTION | 050608-002 | Dec 31, 1986 | AP | RX | Yes | Yes | Start Trial | Start Trial | ||||
| Pfizer | CEFOBID IN PLASTIC CONTAINER | cefoperazone sodium | INJECTABLE;INJECTION | 050613-001 | Jul 23, 1986 | DISCN | No | No | Start Trial | Start Trial | |||||
| Pfizer | DAYPRO | oxaprozin | TABLET;ORAL | 018841-004 | Oct 29, 1992 | AB | RX | Yes | Yes | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pfizer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-001 | Feb 26, 1996 | 4,612,008 | Start Trial |
| Pfizer | TIKOSYN | dofetilide | CAPSULE;ORAL | 020931-002 | Oct 1, 1999 | 4,959,366 | Start Trial |
| Pfizer | TROVAN PRESERVATIVE FREE | alatrofloxacin mesylate | INJECTABLE;INJECTION | 020760-001 | Dec 18, 1997 | 5,763,454 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PFIZER drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 330 mg | ➤ Subscribe | 2018-01-29 |
| ➤ Subscribe | Extended-release Tablets | 330 mg | ➤ Subscribe | 2018-01-29 |
| ➤ Subscribe | Extended-release Tablets | 4 mg and 8 mg | ➤ Subscribe | 2012-10-31 |
| ➤ Subscribe | Injection | 20 mg/mL, 2 mL and 5 mL vials | ➤ Subscribe | 2004-07-26 |
| ➤ Subscribe | Capsules | 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg | ➤ Subscribe | 2008-12-30 |
| ➤ Subscribe | Capsules | 5 mg and 10 mg | ➤ Subscribe | 2005-06-21 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2011-06-17 |
| ➤ Subscribe | Delayed-release Tablets | 50 mg/0.2 mg | ➤ Subscribe | 2009-06-29 |
| ➤ Subscribe | Extended-release Tablets | 82.5 mg and 165 mg | ➤ Subscribe | 2018-02-02 |
| ➤ Subscribe | Extended-release Tablets | 82.5 mg and 165 mg | ➤ Subscribe | 2018-02-02 |
| ➤ Subscribe | Extended-release Tablets | 11 mg | ➤ Subscribe | 2016-11-07 |
| ➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
| ➤ Subscribe | Capsules | 75 mg, 100 mg and 125 mg | ➤ Subscribe | 2019-02-04 |
| ➤ Subscribe | Oral Solution | 20 mg/mL | ➤ Subscribe | 2010-05-19 |
| ➤ Subscribe | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | ➤ Subscribe | 2014-05-01 |
| ➤ Subscribe | Delayed-release Tablets | 75 mg/0.2 mg | ➤ Subscribe | 2008-11-28 |
International Patents for Pfizer Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 2011001328 | Start Trial |
| New Zealand | 518884 | Start Trial |
| Taiwan | I633103 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pfizer Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1666481 | 300887 | Netherlands | Start Trial | PRODUCT NAME: TOFACITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER TOFACITINIBCITRAAT; REGISTRATION NO/DATE: EU/1/17/1178 20170324 |
| 0208846 | SPC/GB99/024 | United Kingdom | Start Trial | PRODUCT NAME: N-(3-(3-CYANOPYRAZOLO(1,5-A)PYRIMIDIN-7-YL)PHENYL)-N-ETHYLACETAMIDE (ZALEPLON); REGISTERED: UK EU/1/99/099/001 19990312; UK EU/1/99/099/002 19990312; UK EU/1/99/099/003 19990312; UK EU/1/99/099/004 19990312; UK EU/1/99/099/005 19990312; UK EU/1/99/099/006 19990312; UK EU/1/99/102/001 19990312; UK EU/1/99/102/002 19990312; UK EU/1/99/102/003 19990312; UK EU/1/99/102/004 19990312; UK EU/1/99/102/005 19990312; UK EU/1/99/102/006 19990312 |
| 2603514 | CA 2019 00015 | Denmark | Start Trial | PRODUCT NAME: EN KOMBINATION AF VABORBACTAM, OG/ELLER ET SALT OG/ELLER HYDRAT DERAF, OG MEROPENEM, OG/ELLER ET SALT OG/ELLER HYDRAT DERAF, SAERLIGT MEROPENEM TRIHYDRAT; REG. NO/DATE: EU/1/18/1334 20181122 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
